Nicholas T Curtis Net Worth

The estimated Net Worth of Nicholas T Curtis is at least $3.42 Millón dollars as of 12 May 2008. Nicholas Curtis owns over 5,000 units of Staar Surgical Co stock worth over $3,424,727 and over the last 21 years Nicholas sold STAA stock worth over $0.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Nicholas Curtis STAA stock SEC Form 4 insiders trading

Nicholas has made over 3 trades of the Staar Surgical Co stock since 2007, according to the Form 4 filled with the SEC. Most recently Nicholas bought 5,000 units of STAA stock worth $14,450 on 12 May 2008.

The largest trade Nicholas's ever made was exercising 56,677 units of Staar Surgical Co stock on 14 June 2007 worth over $195,536. On average, Nicholas trades about 11,429 units every 48 days since 2004. As of 12 May 2008 Nicholas still owns at least 112,990 units of Staar Surgical Co stock.

You can see the complete history of Nicholas Curtis stock trades at the bottom of the page.

What's Nicholas Curtis's mailing address?

Nicholas's mailing address filed with the SEC is 1911 WALKER AVENUE, , MONROVIA, CA, 91016.

Insiders trading at Staar Surgical Co

Over the last 21 years, insiders at Staar Surgical Co have traded over $305,974,767 worth of Staar Surgical Co stock and bought 10,576,326 units worth $122,359,752 . The most active insiders traders include Partners, L.P.Broadwood Cap..., Partners, L.P.Bradsher Neal... y Gilbert H Kliman. On average, Staar Surgical Co executives and independent directors trade stock every 26 days with the average trade being worth of $1,643,742. The most recent stock trade was executed by Arthur C Butcher on 12 August 2024, trading 1,315 units of STAA stock currently worth $49,957.

What does Staar Surgical Co do?

staar surgical company (nasdaq: staa), a leading developer, manufacturer and marketer of implantable lenses and companion delivery systems for the eye has been dedicated solely to ophthalmic surgery for over 30 years. the company offers the evo visian implantable collamer® lenses (icls) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia; and hyperopic icl, which treats far-sightedness. these lenses are intended to provide visual freedom for patients, lessening or eliminating the reliance on glasses or contact lenses. all of these lenses are foldable, which permits the surgeon to insert them through a small incision. staar's lens used in refractive surgery is called an implantable collamer lens or "icl"​. nearly 600,000 visian icls have been implanted to date. it also provides minimally invasive intraocular lenses (iols), including foldable iols for use in minimally invasive cataract surgical procedures; aspheric iols that produce a clearer image than trad

Complete history of Nicholas Curtis stock trades at Staar Surgical Co

Staar Surgical Co executives and stock owners

Staar Surgical Co executives and other stock owners filed with the SEC include:

• Caren Mason,
  President, Chief Executive Officer, Director
• Scott Barnes,
  Chief Medical Officer
• Keith Holliday,
  Chief Technology Officer
• Caren L. Mason,
  CEO, Pres & Director
• Hans-Martin Blickensdoerfer,
  Senior Vice President - Commercial Operations, Direct Markets Europe and China
• Samuel Gesten,
  Chief Legal Officer, Corporate Secretary
• Dr. Scott D. Barnes M.D.,
  Chief Medical Officer
• James Francese,
  Senior Vice President - Commercial Operations, North America and APAC
• Hans-Martin Blickensdoerfer,
  Sr. VP of Commercial Operations and Director of Markets - Europe & China
• Dr. Keith Holliday,
  Chief Technology Officer
• Patrick F. Williams,
  Chief Financial Officer
• Louis Silverman,
  Independent Chairman of the Board
• Stephen Farrell,
  Independent Director
• John Moore,
  Independent Director
• Patrick Williams,
  Chief Financial Officer
• Gilbert Kliman,
  Director
• Thomas Frinzi,
  Director
• Brian Moore,
  IR Contact Officer
• Jon Hayashida,
  Vice President - Global Clinical and Medical Affairs
• Graydon Hansen,
  Chief Manufacturing Officer and Senior Vice President, Global Operations
• Philippe Subrin,
  VP of Collamer Lens Manufacturing & GM of Nidau Operations
• Joanne Egamino Ph.D.,
  Global Head of Clinical Operations
• James Francese,
  Sr. VP of Commercial Operations - North America & APAC
• William Goodmen,
  VP of Global HR
• Samuel J. Gesten,
  Chief Legal Officer & Corp. Sec.
• Lou Silverman,
  Director
• Stephen P Brown,
  Vice President & Chief Financi
• Richard A Meier,
  Director
• Partners, L.P.Broadwood Cap...,
  
• Partners, L.P.Bradsher Neal...,
  
• William P Wall,
  Director
• David Bailey,
  President and CEO
• Robert Studholme,
  Senior VP, Operations
• Wei Jiang,
  
• Arthur C Butcher,
  
• Nathaniel Sisitsky,
  General Counsel
• Nicholas T Curtis,
  Sr. VP Sales and Marketing
• Paul Hambrick,
  Vice President, Operations
• Robert Kenneth Lally,
  Vice President, QA/RA
• David L Schlotterbeck,
  Director
• James I Farnworth,
  VP Reg Affairs & Quality
• Gunther Roepstorff,
  President - Domilens GmbH
• John R Gilbert,
  Director
• Thomas R Paul,
  Vice President - R & D
• John Bily,
  Chief Financial Officer
• Volker D Anhaeusser,
  Director
• John S Santos,
  Sr. VP Planning & Corp Dev
• Jack Steven Roush,
  
• Charles P Slacik,
  Director
• Robin Hughes,
  Vice President, Marketing
• Mark B Logan,
  Director
• Barry G Caldwell,
  Director
• Don M Bailey,
  Director
• Kathryn Tunstall,
  Director
• Philippe Subrin,
  VP Switzerland OP
• Charles S Kaufman,
  V.P. , General Counsel
• Donald J Todd,
  President, Asia/Pacific
• Donald L Fagen,
  V.P. Sales for N. America
• David R Morrison,
  Director
• Craig Felberg,
  VP, R&D and Clinical Affairs
• William Walter Goodmen,
  Global VP, Human Resources
• Donald Duffy,
  Director
• Isamu Kamijo,
  President, STAAR Japan Inc.
• K Peony Yu,
  Director
• Aimee S Weisner,
  
• Magda Michna,
  Chief Clinical, Regulatory,
• Warren Foust,
  Chief Operating Officer
• Elizabeth Yeu Lin,
  
• Lilian Yansheng Zhou,